Novartis said FDA has accepted the company’s Biologics License Application filing and granted priority review for CTL019 (tisagenlecleucel-T), an investigational chimeric antigen receptor T cell therapy, in relapsed and refractory pediatric and young adult patients with B-cell acute lymphoblastic leukemia.
When President Donald Trump on Feb. 3 signed H.R.7148, a package funding most of the federal government through FY26, many in oncology released a long-held sigh of relief.
